drugset / Trial / NCT05889299
Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).
Timeline
- Start
- 2022-12-09
- Primary completion
- 2025-11-03
- Completion
- 2025-11-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ZALTENIBART | Monoclonal antibody | 5 mg/kg | — |
| Subject | ZALTENIBART | Monoclonal antibody | 8 mg/kg | — |